Cover Image
市場調查報告書

全球肽治療市場、開發平台分析

Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016

出版商 PNS Pharma 商品編碼 302551
出版日期 內容資訊 英文 1200 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球肽治療市場、開發平台分析 Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016
出版日期: 2016年03月16日 內容資訊: 英文 1200 Pages
簡介

本報告提供全球肽治療市場相關調查,市場概要,國家,適應症,各相位的開發平台分析,各肽類的肽開發平台,競爭情形,正在開發的肽,及上市肽等彙整資料,為您概述為以下內容。

第1章 簡介

第2章 作用機制:肽治療藥,肽疫苗及肽激素

第3章 全球肽治療藥市場概要

  • 目前的市場情勢
  • 全球肽開發平台概要

第4章 全球肽治療藥市場力學

  • 市場成長的促進要素
  • 商品化的課題

第5章 全球肽治療藥市場展望

第6章 環狀肽的開發平台:國家,適應症,各相位

  • 到預註冊為止的前臨床課程

第7章 雙勝肽:國家,適應症,各相位

  • 到預註冊為止的前臨床課程

第8章 縮酚酸肽:國家,適應症,各相位

  • 到第三階段為止的研究

第9章 醣勝肽:國家,適應症,各相位

  • 到第三階段為止的前臨床課程

第10章 胰島素的開發平台:國家,適應症,各相位

  • 到登記為止的前臨床課程

第11章 脂勝肽:國家,適應症,各相位

  • 到第三階段為止的研究

第12章 利鈉肽:國家,適應症,各相位

  • 到第三階段為止的前臨床課程

第13章 神經肽:國家,適應症,各相位

  • 到第二階段為止的前臨床課程

第14章 寡肽:國家,適應症,各相位

  • 到預註冊為止的研究

第15章 類鴉片肽:國家,適應症,各相位

  • 到預註冊為止的前臨床課程

第16章 肽的開發平台:國家,適應症,各相位

  • 到登記為止的研究

第17章 複合肽的開發平台:國家,適應症,各相位

  • 到預註冊為止的研究

第18章 上市肽的開發平台:國家,適應症,各相位

第19章 競爭情形

  • Amgen
  • Amylin Pharmaceuticals
  • Apitope Technology
  • BioPartners
  • BiondVax Pharmaceuticals Ltd
  • Boehringer Ingelheim
  • Circassia
  • Corden Pharma (Peptisyntha)
  • Eli Lily
  • Galena Biopharmaceuticals
  • GlaxoSmithKline
  • Hyperion Therapeutics
  • ImmunoCellular Therapeutics
  • Ipsen
  • Lonza
  • Merck
  • NovoNordisk
  • Par Pharmaceuticals
  • PeptiDream
  • Roche
  • Sanofi
  • Tarix Pharmaceuticals

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Investigators are looking for different molecular entities that could be used for the development of viable therapeutics with commercial potential. Peptide therapeutics are one such category that has gained significant attention in past years. Several products have been launched in global market for different indications. Significant investments have been made by pharmaceutical companies in research and development (R&D) segment in order to come forth with innovative products. They also serve as building blocks for other therapeutics due to which it has become essential to study their nature in depth. In this way, it could be expected that peptide therapeutics for different ailments would be commercialized in global market in coming years.

Pharmacological profiles of peptide therapeutics is quite good due to which their numbers are increasing in global market. Inherently, peptide therapeutic offers various benefits like higher safety and efficacy levels along with higher tolerability. Metabolism of peptide therapeutics is quite predictable and it can be changed by investigators. In this way, higher control over pharmacological parameters could be observed. They can also be developed synthetically due to which variability could be made during their development. In this way, they are highly malleable and could be changes according to the requirements of drug development program. Their rate of development is high and low attrition rates related to peptide therapeutics have been also observed.

Pipeline of peptide therapeutics is quite strong due to which new products are expected to enter in global market in coming years. Several peptide therapeutics have already entered in various phases of clinical trials. Development of positive results will accelerate their market introduction in coming years. They are peptide in nature due to which chances of degradation is high, poor chemical stability and absorbance are some common caveats with their development. Immunogenicity is another factor that affect the efficacy of peptide therapeutics as some patients may develop severe side effects. Investigators have developed various procedure by which they are able to increase potency of peptide products. In this way, it could be observed that investigators are actively engaged in the development of peptide therapeutics.

Rapid discovery of peptide therapeutics is expected to increase the number of products in global market. Investigators are developing methods to identify new lead molecules that will serve as a basis for the development of new molecule. They are also being administrated in combination with other drugs to achieve higher therapeutic benefits. Alternate Route of Administration (RoA) is also being discovered for peptide drugs so as to maintain their efficacy. They are expected to have competition with small molecule drugs and development of new technologies which can hamper their marketing potential. Higher prices are other major factors that affect the commercialization potential of peptide therapeutics in global market. These factors have to consider by pharmaceutical companies while formulating marketing strategies.

Peptide therapeutics are versatile in nature due to which they can be used for the treatment of various disorders. Cancer, Central Nervous System (CNS), cardiovascular diseases, respiratory diseases and metabolic disorders are some the major segments where presence of peptide therapeutics could be observed. Besides this, different types of insulin has been developed by engineering peptide molecules. Their pharmacological efficacy is expected to be improved with time and new molecules are expected to enter in global market. Pharmaceutical companies have to come forth with new molecules in order to increase market shares of peptide therapeutics. Strong clinical pipeline indicates that the pharmaceutical firms are actively engaged in the development of peptide therapeutics. In this way, it could be expected that market size of global peptide therapeutics market will increase in coming years.

Peptide Segment Included In Report:

Cyclic-Peptide, Polypeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin

"Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016" Report Highlights:

  • Introduction to Peptides
  • Mechanism of Action: Peptide Therapeutics, Peptide Vaccine & Peptide Hormone
  • Global Peptide Therapeutics Market Dynamics
  • Global Peptide Clinical Pipeline by Company, Indication & Phase
  • Global Peptide Pipeline: 722 Peptides
  • Majority Peptides in Preclinical Phase: 308 Peptides
  • Commercially Available Peptides: 136 Peptides

Table of Contents

1. Introduction to Peptides

2. Mechanism of Action: Peptide Therapeutics, Peptide Vaccine & Peptide Hormone

  • 2.1 Peptide Therapeutics
  • 2.2 Peptide Vaccine
  • 2.3 Peptide Hormone

3. Global Peptide Therapeutics Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Global Peptide Pipeline Overview

4. Global Peptide Therapeutics Market Dynamics

  • 4.1 Market Growth Drivers
    • 4.1.1 Escalating Demand for Better Therapeutics
    • 4.1.2 Research & Development
    • 4.1.3 Advanced Peptide Synthesis Technology
    • 4.1.4 Multiple Disease Indications
    • 4.1.5 Strong Clinical Pipeline
  • 4.2 Peptide Therapeutics Commercialization Challenges

5. Global Peptide Therapeutics Market Future Prospects

6. Cyclic Peptides Cinical Insight by Company, Indication & Phase

  • 6.1 Preclinical till Preregistration

7. Dipeptides Cinical Insight by Company, Indication & Phase

  • 7.1 Preclinical till Preregistration

8. Depsipeptides Cinical Insight by Company, Indication & Phase

  • 8.1 Research till Phase-III

9. Glycopeptide Cinical Insight by Company, Indication & Phase

  • 9.1 Preclinical till Phase-II

10. Insulin Cinical Insight by Company, Indication & Phase

  • 10.1 Preclinical till Registered

11. Lipopeptides Cinical Insight by Company, Indication & Phase

  • 11.1 Research till Phase-III

12. Natriuretic Peptide Cinical Insight by Company, Indication & Phase

  • 12.1 Preclinical till Phase-III

13. Neuropeptide Cinical Insight by Company, Indication & Phase

  • 13.1 Preclinical till Phase-II

14. Oligopeptides Cinical Insight by Company, Indication & Phase

  • 14.1 Research till Preregistration

15. Opioid-Peptide Cinical Insight by Company, Indication & Phase

  • 15.1 Preclinical till Preregistration

16. Peptides Cinical Insight by Company, Indication & Phase

  • 16.1 Research till Registered

17. Multiple Peptides Cinical Insight by Company, Indication & Phase

  • 17.1 Research till Preregistration

18. Marketed Peptides Cinical Insight by Company, Indication & Phase

  • 18.1 Cyclic Peptides
  • 18.2 Dipeptides
  • 18.3 Depsipeptides
  • 18.4 Glycopeptides
  • 18.5 Insulins
  • 18.6 Natriuretic-Peptides
  • 18.7 Neuropeptides
  • 18.8 Oligopeptides
  • 18.9 Opioid-Peptides
  • 18.10 Peptides
  • 18.11 Multiple Peptides

19. Competitive Landscape

  • 19.1 Amgen
  • 19.2 Amylin Pharmaceuticals
  • 19.3 Apitope Technology
  • 19.4 BioPartners
  • 19.5 BiondVax Pharmaceuticals Ltd
  • 19.6 Boehringer Ingelheim
  • 19.7 Circassia
  • 19.8 Corden Pharma (Peptisyntha)
  • 19.9 Eli Lily
  • 19.10 Galena Biopharmaceuticals
  • 19.11 GlaxoSmithKline
  • 19.12 Hyperion Therapeutics
  • 19.13 ImmunoCellular Therapeutics
  • 19.14 Ipsen
  • 19.15 Lonza
  • 19.16 Merck
  • 19.17 NovoNordisk
  • 19.18 Par Pharmaceuticals
  • 19.19 PeptiDream
  • 19.20 Roche
  • 19.21 Sanofi
  • 19.22 Tarix Pharmaceuticals

List of Figures

  • Figure 1-1: Components of Peptide
  • Figure 1-2: Features of Peptide Therapeutics
  • Figure 2-1: Benefits of Peptide Modifications
  • Figure 2-2: Benefits of Computational Methods
  • Figure 2-3: Different Types of Peptide Formulation Vehicles
  • Figure 2-4: Mechanism of Vibativ
  • Figure 2-5: Mechanism of Liraglutide
  • Figure 2-6: Mechanism of Goserelin
  • Figure 2-7: Formulation of Orally Administrated Peptide Therapeutics
  • Figure 2-8: Mechanism of Peptide Vaccines
  • Figure 2-9: Mechanism of Live Vaccines
  • Figure 2-10: Mechanism of Toxoid & Inactivated Vaccine
  • Figure 2-11: Mode of Action of Peptide Cancer Vaccines
  • Figure 2-12: Mechanism of Peptide Hormones
  • Figure 2-13: Mechanism of Insulin
  • Figure 2-14: Mechanism of Genotropin
  • Figure 2-15: Mechanism of Pitressin
  • Figure 2-16: Mechanism of Glucagon
  • Figure 3-1: Global Peptide Market (US$ Billion), 2014-2020
  • Figure 3-2: Peptide Pipeline by Phase (%), 2016
  • Figure 3-3: Peptide Pipeline by Phase (Numbers), 2016
  • Figure 3-4: Cyclic Peptides Pipeline by Phase (%), 2016
  • Figure 3-5: Cyclic Peptides Pipeline by Phase (Numbers), 2016
  • Figure 3-6: Dipeptides Pipeline by Phase (%), 2016
  • Figure 3-7: Dipeptides Pipeline by Phase (Numbers), 2016
  • Figure 3-8: Depsipeptides Pipeline by Phase (%), 2016
  • Figure 3-9: Depsipeptides Pipeline by Phase (Numbers), 2016
  • Figure 3-10: Glycopeptides Pipeline by Phase (%), 2016
  • Figure 3-11: Glycopeptides Pipeline by Phase (Numbers), 2016
  • Figure 3-12: Insulin Pipeline by Phase (%), 2016
  • Figure 3-13: Insulin Pipeline by Phase (Numbers), 2016
  • Figure 3-14: Lipopeptides Pipeline by Phase (%), 2016
  • Figure 3-15: Lipopeptides Pipeline by Phase (Numbers), 2016
  • Figure 3-16: Natriuretic Peptides Pipeline by Phase (%), 2016
  • Figure 3-17: Natriuretic Peptides Pipeline by Phase (Numbers), 2016
  • Figure 3-18: Neuropeptides Pipeline by Phase (%), 2016
  • Figure 3-19: Neuropeptides Pipeline by Phase (Numbers), 2016
  • Figure 3-20: Oligopeptides Pipeline by Phase (%), 2016
  • Figure 3-21: Oligopeptides Pipeline by Phase (Numbers), 2016
  • Figure 3-22: Opioid-Peptides Pipeline by Phase (%), 2016
  • Figure 3-23: Opioid-Peptides Pipeline by Phase (Numbers), 2016
  • Figure 3-24: Multiple Peptides Pipeline by Phase (%), 2016
  • Figure 3-25: Multiple Peptides Pipeline by Phase (Numbers), 2016
  • Figure 4-1: Global Peptide Therapeutics Market Growth Drivers
  • Figure 4-2: Global Peptide Therapeutics Market Commercialization Challenges
Back to Top